{"tag":"cell-therapy"}

Gilead Sciences: HIV Dominance, Oncology Expansion, and Biotech Franchise Value

Gilead Sciences is a biopharmaceutical company that dominates HIV treatment globally with $20.8 billion in HIV revenue (FY2025). This explainer covers the HIV franchise (Biktarvy, Yeztugo), oncology (Trodelvy, CAR-T), liver disease (Livdelzi), pipeline strategy, capital allocation, and key risks.

May 26, 2026